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Abstract
Background and aims Alpha-1 antitrypsin (AAT) is a product of SERPINA1 gene mainly expressed by hepatocytes. Clinically 
relevant mutations in the SERPINA1 gene, such as Z (Glu342Lys), results in an expression of misfolded AAT protein having 
high propensity to polymerize, accumulate in hepatocytes and thus to enhance a risk for hepatocyte damage and subsequent 
liver disease. So far, the relationship between the Z-AAT accumulation and liver cell damage remains not completely under-
stood. We present three-dimensional organoid culture systems, as a novel tool for modeling Z-AAT-related liver diseases.
Methods We have established liver organoids from liver biopsies of patients with homozygous (ZZ) and heterozygous (MZ) 
deficiency and normal (MM) genotypes of AAT. The features of these organoid models were characterized by analyzing 
AAT protein secretion and intracellular aggregation in MZ and ZZ genotypes as well as SERPINA1 expression in differenti-
ated cultures.
Results Transcriptional analysis of differentiated organoid cultures by RNA-Seq showed hepatocyte-specific gene expres-
sion profile. Genes, such as ALB, APOB, CYP3A4 and SERPINA1, were validated and confirmed through quantitative-PCR 
analysis. The organoids from MZ and ZZ cases showed intracellular aggregation and lower secretion of AAT protein, and 
lower expression of ALB and APOB, as typically seen in hepatocytes from Z-AAT deficiency patients. Furthermore, organoids 
responded to external stimulus. Treatment with oncostatin M, a well-known inducer of SERPINA1, increased expression of 
the full-length transcripts (AAT-1C) as well as the short transcript of AAT (AAT-ST1C4).
Conclusions Liver organoid model recapitulates the key features of Z-AAT deficiency and provides a useful tool for disease 
modeling.
Keywords Organoids · Liver · Alpha-1 antitrypsin deficiency · Oncostatin M · RNA-seq · SERPINA1
Introduction
Alpha1-antitrypsin (AAT), a prototypic member of the ser-
ine protease inhibitor (serpin) superfamily, is mainly pro-
duced by hepatocytes. A normal concentration of the AAT in 
human blood ranges between 1 and 2 g/l and it is estimated 
that liver accounts for about 80% of the total circulating 
AAT [1]. Human AAT is also an acute phase glycoprotein 
with broad anti-protease and anti-inflammatory functions, 
and therefore AAT deficiency leads to various health prob-
lems, including liver disorders [2].
AAT is encoded by the SERPINA1 gene located at the 
distal end of the long arm of chromosome 14. The typical 
SERPINA1 gene consists of two alleles, named M, which 
are responsible for the synthesis of quantitatively and quali-
tatively normal AAT. The most frequent deficient alleles 
are so called S (Glu264Val) and Z (Glu342Lys). The com-
binations of the M, S and Z alleles give rise to the different 
genotypes MM, SS, MZ, SZ and ZZ. The homozygous ZZ 
genotype is the most relevant genotype in the clinical and 
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genetic knowledge of SERPINA1, which results in about 
90% reduced levels of circulating AAT protein. The defi-
ciency in ZZ cases occurs due to the aberrant folding of the 
Z-AAT causing its polymerization and intracellular accumu-
lation. The clinical manifestations of severe AAT deficiency 
include liver (intracellular retention of aggregated AAT that 
resists degradation) and lung (missing protective levels of 
functional AAT) diseases, and less frequently skin diseases 
such as panniculitis or ANCA + vasculitis [3].
The AAT deficiency-related liver damage can occur at 
any age. Clinical studies have shown that children who 
progressed to the end-stage liver disease had more severe 
abnormalities in infancy such as persistent jaundice for 
more than 6 weeks, hepatomegaly, higher transaminases and 
severe morphological changes including bile duct reduplica-
tion, fibrosis and cirrhosis. Currently, however, there are no 
distinguishable features/markers allowing to predict which 
child will develop a fast decline in liver function requiring 
liver transplantation or who will recover without sequelae 
of chronic liver disease [4]. In adults, liver damage can be 
manifested by liver fibrosis and cirrhosis, and hepatocellu-
lar carcinoma [3, 5]. On the other hand, Z-AAT deficiency 
carriers may remain clinically healthy until later adult-
hood. This variability in clinical presentation suggests that 
in addition to inherited abnormality in AAT protein, other 
environmental, genetic and epigenetic factors are necessary 
to promote the development of the AAT deficiency-related 
liver disease. Therefore, better understanding of the molecu-
lar mechanisms underlying liver disease related to Z-AAT 
deficiency is of critical importance for the diagnosis and the 
development of specific and personalized therapies.
Currently, experimental studies investigating liver disease 
in AAT deficiency are limited by the difficulty to obtain 
human liver tissue and to maintain primary cultures of 
human hepatocytes. Alternatively, human embryonic stem 
cells and induced pluripotent stem cells are used [6]. How-
ever, full differentiation of stem cells into mature hepato-
cytes has yet not been reported.
Organoids are new three-dimensional (3D) model sys-
tems referred to a group of cells growing in a 3D structure 
that are generated from primary tissues or cells, with self-
renewal and self-organization capacity, maintaining similar 
appearance and functionality as the original tissue. Adult 
tissue-derived organoids can be maintained through indefi-
nite passage and preserve genetic stability [7]. Recently, 
human liver organoids started to be used for the studies of 
various liver diseases [8, 9]. The first described human liver 
organoids allowed the expansion of adult liver stem cells and 
subsequent differentiation to hepatocytes that recapitulate 
some function of ex vivo liver tissue. Moreover, differenti-
ated liver organoids from AAT-deficient patients mimicked 
the characteristics of the disease [7]. In this study, we have 
established and compared adult human liver organoids from 
liver biopsies of individuals with normal, MM and deficient 
ZZ and MZ AAT genotypes. The aim was to show if liver 
organoid cultures can recapitulate the typical features of 
liver cells expressing normal and deficient AAT and can be 
useful for AAT deficiency-related liver disease modeling. 
Typical features of AAT deficiency-associated liver disease 
were analyzed in terms of AAT polymerization and secre-
tion, and transcriptional induction of SERPINA1 gene tran-
scripts in organoids subjected to external stimuli. The results 
show that liver organoids is a useful tool allowing modeling 
liver disease in individuals with different AAT mutations.
Materials and methods
Patients and genotyping
Organoids were established from liver biopsies collected 
from patients and controls at the Hospital 12 de Octubre in 
Madrid (Spain) and also provided by Dr. Huch at Cambridge 
University (UK). The ZZ organoids were derived from ZZ 
AATD patients with hepatic failure who had liver transplant, 
whereas MZ organoids were obtained from an adult MZ 
AATD patient who underwent colicestomy. The control MM 
AAT organoids were derived from an individual with hepa-
tocellular carcinoma undergoing surgical resection. Tissue 
sample was obtained from macroscopically defined non-
neoplastic adjacent area. All biopsies were genotyped for 
SERPINA1. Sequencing of SERPINA1 gene coding exons 
was performed by using previously described primers [10, 
11] in an automatic sequencer (ABI PRISM 377 Applied 
BioSystems). Signed informed consent for the study was 
obtained from all the subjects and the research was approved 
by the ethics committee of Instituto de Salud Carlos III, 
Madrid, Spain.
Establishment and culture of human liver organoids
We aimed to generate liver organoids expressing ZZ and 
MZ genotypes of AAT, and normal MM variant of AAT. 
Following the protocol described by Huch and collaborators 
[7, 12], we established liver organoids from ductal cells of 
human liver. Briefly, after surgical excision, the tissue was 
kept cold in basal medium (Advanced DMEM/F12, 1% peni-
cillin/streptomycin, 1% Glutamax, 10 mM Hepes) until pro-
cessing. The tissue was minced, washed with cold medium 
(DMEM, Glutamax, DGlu, Pyruvato, 1% FBS, 1% penicil-
lin/streptomycin) and digested (Earle’s Balance Salt Solution 
(EBSS), collagenase D 2.5 mg/ml, DNAse I 0.1 mg/ml). 
After centrifugation, cells were resuspended in a basement 
matrix and seeded in a 24-well plate with isolation medium 
(basal medium supplemented with 25 ng/ml recombinant 
human Nogging, 30% conditioned medium with Wnt3a 
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and 10 μM Rho kinase (Rock inhibitor)). In this specific 
culture condition, only progenitor adult stem cells, mainly 
located in ducts, are able to grow forming self-renewing 
organoids in the form of spheres. In each passage, organoids 
were removed from the basement matrix and transferred to 
fresh matrix. For expansion, the undifferentiated organoids 
were cultured in an expansion medium (EM) (basal medium, 
1 mM N-acetylcysteine, 5% conditioned medium Rspo1, 
10 mM nicotinamide, 10 nM recombinant human gastrin I, 
50 ng/ml recombinant EGF, 100 ng/ml recombinant human 
fibroblast growth factor (FGF) 10, 50 ng/ml recombinant 
human hepatocyte growth factor (HGF), supplemented with 
10 μM Rho kinase (Rock inhibitor)). The differentiation into 
hepatocytes was achieved with a differentiation medium 
(DM) (basal medium, 1:50 B27 supplement with or without 
vitamin A, 1:100 N2 supplement, 1 mM N-acetylcysteine, 
10 nM recombinant human-gastrin I, 50 ng/ml recombinant 
mouse EGF, 100 ng/ml recombinant human FGF10, 50 nM 
A83-01, 10uM γ-secretase inhibitor (DAPT). Figure 1 illus-
trates different stages of the isolation, expansion and differ-
entiation of the liver organoid.
Identification of Z‑AAT aggregates by using PAS‑D 
staining
To detect intracellular aggregates of the Z-AAT protein, 
cytospins of organoid liver cells were stained with the peri-
odic acid–Schiff–diastase (PAS-D). Organoids were washed 
with phosphate-buffered saline (PBS), spread on slides 
(1 min at 600 rpm) and fixed with 95% ethanol for 5 min. 
Afterward, cells were washed twice with PBS and stained 
with hematoxylin–eosin and PAS-D.
Detection of intracellular AAT 
by immunofluorescence
Organoids growing in EM (undifferentiated) for 1–2 months 
or differentiated organoids growing in DM for 2 weeks were 
collected for immunofluorescence detection of total AAT or 
polymers of AAT. Cytospins of organoid cells were washed 
with PBS, fixed with 95% ethanol and permeabilized with 
0.1% Triton X-100/PBS and blocked with 1% bovine serum 
albumin/phosphate-buffered saline (BSA/PBS). The expres-
sion of AAT protein was analyzed by incubating with anti-
AAT B9 antibodies (sc-59438 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) for total AAT and with D11 antibody 
specific for AAT polymers (provided by Sabina Janciausk-
iene, Hannover). A secondary anti-mouse FICT IGG (Sigma 
F0257) antibody was used. 4′, 6-diamidino-2-phenylindole 
(DAPI Sigma) staining of cell nuclei was performed. The 
preparations were examined under a fluorescence micro-
scope Zeiss Ax10. The proportion of positive cells showing 
AAT polymers (D11) was estimated by counting at least 
300 nuclei from three different fields from MM, MZ and 
ZZ organoids (counting was performed by two independent 
researchers).
Western blot analysis of AAT 
Native and polymeric forms of AAT protein were detected 
in cell pellets and culture medium of expanding and differ-
entiated organoids. Cell pellets were lysed with RIPA buffer 
containing a cocktail of complete protease inhibitors (Roche, 
Mannhein, Germany). The lysates and culture media were 
electrophoresed on 10% polyacrylamide sodium dodecyl sul-
fate PAGE (SDS-PAGE). The insoluble fraction was soni-
cated and separated on non-denaturing 8% PAGE. Proteins 
were detected with the following primary antibodies: anti-
AAT B9 (1:100 dilution) and anti-beta-actin (AC-74 Sigma 
Aldrich, Taufkirchen, Germany) (1:5000 dilution) followed 
by chicken anti-mouse IgG-HRP (sc-2954 Santa Cruz Bio-
technology) (1:5000 dilution), and visualized after labeling 
with Immobilon HRP substrate (Millipore) using Chemidoc 
Touch imaging system (Biorad, Hercules, CA, USA). Quan-
tification of the western blot bands of AAT protein of MM, 
MZ and ZZ organoids was performed with Image J software.
Fig. 1  Representative images of the expansion and differentiation of 
liver organoids. a Human liver organoids were obtained from a liver 
biopsy of patients. b Ductal cells are isolated, c, d Liver organoids 
are developed by growing in an expansion medium (EM) and a 3D 
Matrigel, e, f Cultured in differentiation medium (DM) giving rise 
to differentiated organoids (magnification ×10). Microscope Leica 
DMIL LED, camera Leica MC170HD
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Transcriptomic analysis of liver organoids (RNA‑Seq)
Total RNA was isolated from organoid cells using TriRea-
gent (Sigma) followed by DNase1 digestion step to ensure 
that the samples were not contaminated with genomic 
DNA. The purity of RNA was assessed using Agilent RNA 
6000 Nano Kit and the Agilent 2100 Bioanalyzer. TruSeq 
Stranded mRNA Kit (Illumina) was used for library prepa-
ration based on the recommendations from the manufac-
turer. The sequencing of the library was performed at the 
Genomics service (ISCIII) on a NextSeq 500 sequencer 
using 75 base read lengths in paired-end mode. The obtained 
RNA-Seq data were analyzed by the Bioinformatics Facil-
ity (ISCIII). First, quality control analysis involving fastQC 
v0.11.3 (http://www.bioin forma tics.babra ham.ac.uk/proje 
cts/fastq c/) was carried out, and any adapter sequences 
as well as low quality 3′ ends were removed using Trim-
momatic v0.36. The high-quality reads were then mapped 
against Hg38 human genome using Tophat v2.0.14 and map-
ping quality control was performed using RseQC v2.6.4. 
Transcriptome prediction and gene/isoform quantification 
was calculated using Cufflinks v2.2.1 based on Hg38 Ref-
Seq reference genes. Finally, differential expression analysis 
was carried out using cuffdiff. Differentially expressed genes 
(DEGs) were considered when FDR values were < 0.05. The 
CummeR bund R package (v2.14.0) was used for quality 
control and results visualization. The functional analysis 
was carried out with Functional Annotation Tool DAVID 
Bioinformatics Resources 6.8, NIAID/NIH.
Validation of differentiation markers by RT‑qPCR
Progenitor and ductal cell markers, leucine-rich repeat con-
taining G protein-coupled receptor 5 (LGR5) and keratin 19 
(KRT19), and differentiation markers (albumin, ALB; apoli-
poprotein B, APOB; and cytochrome P450 3A4, CYP3A4) 
were analyzed by RT-qPCR. Total RNA was extracted from 
organoids by using TriReagent (Sigma) and expression was 
also analyzed in HepG2 cells and control liver biopsy. cDNA 
was synthesized using Maxima First Strand cDNA Synthesis 
kit (Thermo Scientific, Fermentas Life Sciences, St. Leon-
Rot, Germany). The RT-qPCR of selected hepatocyte mark-
ers was performed in triplicate using Taqman Fast Advance 
master mix (Applied BioSystems) and specific primers and 
probes (Supplementary Table 1). Taqman probes were from 
Universal probe library, UPL, (Roche): KRT19 (#71), LGR5 
(#78), ALB (#44), APOB (#90), CYP3A4 (#50). Amplifica-
tion conditions were as follows: 95 °C for 20 s, 45 dena-
turation cycles at 95 °C for 3 s, annealing at 60° C for 30 s. 
RT-qPCR was performed on the QuantStudio 5 System 
(ThermoFisher Scientific) and the analysis using the soft-
ware QuantStudio Design and Analysis Software v1.4.3. 
Glyceraldehyde-3-phosphate dehydrogenase (GADPH) was 
used as an endogenous control. The relative gene expression 
was calculated by comparative Ct method and obtaining the 
fold-change value (DDCt).
Expression analysis of SERPINA1 transcripts
The expression of alternative SERPINA1 gene transcripts 
was analyzed in RNA from MM, MZ and ZZ organoids 
under both the expansion (EM) and differentiation (DM) 
conditions. The RT-qPCR for SERPINA1 transcripts, gener-
ated by the use of different promoters and alternative splic-
ing between non coding exons 1A, 1B and 1C, was per-
formed with primers and methods previously described [13]. 
In addition, expression of SERPINA1 short transcripts was 
analyzed as described [14].
Exogenous organoid stimulation with OSM
To study the expression regulation of SERPINA1 gene, 
organoids were exposed to oncostatin M (OSM: rhOncos-
tatin M recombinant human E. Coli from RD Systems 295-
OM). We added OSM (50 ng/ml) to organoids at day 14 of 
the differentiation process. After 16 h of stimulation, cells 
were collected and the expression of SERPINA1 transcripts 
was quantified. A Student’s t test analysis was performed to 
compare the gene expression between controls and stimu-
lated cells. Statistically significant values were considered 
if p < 0.05.
Results
Hepatocyte‑specific gene expression 
in differentiated organoids
Transcriptome analysis by RNA-Seq was used to compare 
undifferentiated and differentiated liver organoids inde-
pendently of the genotypes. As expected, a high number 
of differentially expressed genes DEGs (3097 genes) were 
found between the undifferentiated and differentiated 
organoids. The top hundred most differentially expressed 
genes are illustrated in Fig. 2a, which include 48 up-reg-
ulated and 53 down-regulated genes after differentiation. 
Highly induced genes included typical mature hepato-
cyte genes, as previously described by other authors [15, 
16]. The results confirmed that differentiated organoids, 
regardless of the AAT genotype, show increased expres-
sion of hepatocyte-specific genes such as albumin (ALB), 
apolipoprotein B (APOB), apolipoprotein C3 (APOC3), 
cytochromes CYP3A4, CYP2C8 (cytochrome P450 family 
2 subfamily C member 8), as well as metabolism enzymes 
phospholipase A2 group XIIB (PLA2G12B), acyl-CoA 
thioesterase 12 (ACOT12), UDP glucuronosyltransferase 
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family 2 member B4 (UGT2B4), insulin-like growth factor 
2 receptor (IGF2R), UDP glucuronosyltransferase family 2 
member B11(UGT2B11), 3-hydroxy-3-methylglutaryl-CoA 
synthase 2 (HMGCS2), transmembrane serine protease 
6 (TMPRSS6), aminocarboxymuconate semialdehyde 
decarboxylase (ACMSD) and coagulation factor XIII B 
chain (F13B). A complete list of the top 100 most DEGs 
in differentiated organoids can be found in supplementary 
Tables 2 and 3.
The expression of certain progenitor, ductal and hepato-
cyte cell markers were validated in MM and ZZ by RT-
qPCR (Fig. 2b). As expected, both MM and ZZ organoids 
when growing in EM expressed markers of progenitor 
(LGR5) and ductal (KRT19) cell lineage, but these mark-
ers disappeared after differentiation. In contrast, organoids 
cultured in DM highly expressed hepatocyte genes, such as 
albumin (ALB), apolipoprotein B (APOB) and cytochrome 
P450 3A4 (CYP3A4), which were mostly not detected in 
undifferentiated liver organoid cultures. Remarkably, when 
compared to MM AAT organoids, lower expression of the 
APOB and ALB hepatocyte markers, but increased expres-
sion of the CYP3A4, was observed in ZZ AAT organoids.
SERPINA1 gene transcripts expression in liver 
organoids under expansion (EM) and differentiation 
(DM) conditions
The expression of full-length and short (ST1C4) tran-
scripts of SERPINA1 gene [14] was analyzed in MM and 
ZZ AAT-derived liver organoids (Fig. 2c). Higher expres-
sion of all SERPINA1 transcripts was observed in differ-
entiated than in undifferentiated MM and ZZ organoids, 
indicating that SERPINA1 gene is induced with the dif-
ferentiation process in hepatocytes. Moreover, SERPINA1 
expression levels were higher in MM than in ZZ differenti-
ated hepatocytes. Interestingly, in ZZ AAT organoids the 
expression of 1C transcript, the main liver transcript, did 
not increase during the differentiation process (Fig. 2c). 
Only a slight increase in the expression of the other minor 
AAT transcripts originated by the monocyte promoters 
(1A and 1B) was detected. A short ST1C4 transcript of 
SERPINA1 gene was induced in differentiated M and Z 
hepatocytes as compared to undifferentiated organoids.
Fig. 2  Gene expression analysis in human liver organoids. a Heat-
map of the top up-regulated differentially expressed genes between 
undifferentiated organoids (EM) and organoids differentiated into 
hepatocytes (DM). Some of the most relevant mature hepatocyte 
genes are represented at the right side. Darker color means higher 
expression levels. Gene expression analysis of differentiation markers 
in organoids MM (black) and ZZ (red) under expansion and differ-
entiation conditions: b expression of markers of pluripotent (LGR5), 
ductal cells (KRT19) and differentiated hepatocytes (ALB, APOB and 
CYP3A4); c expression of alternative transcripts of SERPINA1 gene 
(1C, 1A and 1B) and short transcripts (ST1C4) in MM and ZZ orga-
noids
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Regulation of SERPINA1 gene transcripts 
by oncostatin M (OSM)
The production of AAT in hepatocytes is controlled by a 
variety of cytokines released during inflammation, whereas 
leading regulators are IL-6-type cytokines. Therefore, we 
next analyzed transcriptional regulation of SERPINA1 gene 
in liver organoids treated with oncostatin M, a pleiotropic 
cytokine that belongs to the IL-6 group of cytokines, a well-
known inducer of AAT production [17]. This analysis was 
performed on both undifferentiated (EM) and differentiated 
(DM) organoids from MM, MZ and ZZ AAT cases (Fig. 3). 
In MM AAT organoids, the 1C full-length transcript of AAT, 
which is typically expressed by hepatocytes, was induced by 
OSM under both EM and DM conditions. However, in ZZ 
organoids, the more evident induction of 1C transcript was 
observed in the differentiated stage. It is important to point 
out that in differentiated hepatocytes, OSM also induced the 
expression of transcripts derived from the monocyte pro-
moter 1A and 1B (Supplementary Fig). Short transcripts 
ST1C4 were highly induced by OSM in differentiated MM 
and MZ AAT organoids, and to a lesser extent in ZZ AAT 
organoids (Fig. 3). No expression of the other described 
short transcript, ST1C5, was detected in the liver organoids.
Detection of PAS‑D‑positive AAT polymers in liver 
organoids
The presence of aberrant AAT polymers positive for PAS 
diastase-resistant (PAS-D) staining within hepatocytes is a 
characteristic feature of Z-AAT-deficient liver [3, 5, 18]. As 
expected, positive PAS-D staining was observed in orga-
noids generated from the ZZ and from MZ AAT patients 
indicating the accumulation of the Z-AAT polymers within 
differentiated organoid cells. By contrast, PAS-D staining 
was negative in MM AAT organoids (Fig. 4).
Detection of total and polymeric form of AAT 
protein in liver organoids
To detect specifically AAT protein, we performed immu-
nofluorescence assays in undifferentiated and differentiated 
organoids from MM, MZ and ZZ AAT cases (Fig. 5). As 
expected, Z-AAT polymers were evident in Z, but not in M 
organoids. In both ZZ and MZ cases, AAT polymers were 
limited to restricted groups of cells or isolated cells. The 
quantification of cells positive for AAT polymer staining 
(D11 antibody) revealed that MZ organoids had around 5% 
of cells with polymer accumulation, approximately half of 
the positive cells found in ZZ organoids (10%) (Fig. 5c).
The western blot analyses revealed the presence of AAT 
protein in the extracellular medium and cell extracts of MM 
and MZ differentiated organoids (Fig. 6). The monomeric 
AAT protein was not detected in the cell extracts and extra-
cellular medium of ZZ AAT organoids. By contrast, we 
found that the largest amount of insoluble AAT was present 
in ZZ compared to MZ or MM organoids (Fig. 6).
Discussion
Inherited AAT deficiency is a common cause of genetic 
liver disease having a wide spectrum of presentations rang-
ing from neonatal liver disease to an incidental finding of 
adulthood end-stage cirrhosis requiring transplantation. 
Currently, there are no biomarkers/predictors to identify 
Fig. 3  Induction of SERPINA1 gene transcripts (1C) and short tran-
scripts (ST1C4) by stimulations with OSM. Relative gene expres-
sion of the analyzed transcripts was measured in organoids grown in 
expansion medium (EM) and in differentiated organoids (DM). Sta-
tistically significant values are shown by * (p < 0.05)
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AAT-deficient patients who will or not develop a severe 
course of liver disease. Moreover, the molecular mechanisms 
of AAT deficiency-related liver diseases remain largely 
unexplored.
Primary human hepatocytes reflect the metabolism and 
functionality of the human liver and are considered as the 
gold standard for hepatic ex vivo studies. However, the 
availability of primary human hepatocytes, especially from 
patients with rare inherited diseases such as AAT deficiency, 
is limited, and the function of isolated hepatocytes is hard to 
maintain ex vivo. When cultured in vitro, these cells undergo 
dedifferentiation, causing them to lose hepatocyte function. 
To solve the above issues, the development of new models 
allowing the culture and study of functional human hepato-
cytes is of great need [19–21].
To date, the 3D organoids are the best available repre-
sentation of the liver cells with several advantages. First, 
organoids permit a long-term expansion with preserved 
genomic stability; second, organoid cultures recapitulate 
hepatocyte functions and allow to study molecular mecha-
nisms of healthy and diseased liver, ex vivo; and third, orga-
noids can be transplanted, as demonstrated in mouse models 
[7, 22], opening new avenues for regenerative medicine and 
gene therapy. These advantages of organoid systems together 
with emerging new technologies (such as 3D printing and 
imaging techniques) significantly contribute to the new 
strategies of how liver diseases are studied, and therapeu-
tics developed.
Extensive analysis of cultured liver organoids revealed 
that the expanded cells preserve their genetic integrity over 
months in culture [7]. These results open up the avenue to 
start using human liver material expanded in vitro as an 
alternative hepatocyte source for studies of rare hereditary 
liver diseases. A variety of monogenic hereditary diseases 
affect the liver specifically, and these should be studied 
individually.
Therefore, in this study we established human liver orga-
noid cultures reproducing the main characteristics of the 
wild-type M and pathogenic, deficient ZZ and MZ variants 
of AAT protein. When compared to 2D cell models [19], 
organoids are closer to liver tissue with respect to morphol-
ogy, gene expression, and protein secretion. For example, the 
liver produces and secretes major proteins into the circula-
tion, such as albumin, AAT, fibrinogens and apolipoproteins. 
Previous studies demonstrated that liver organoid cultures 
are able to express and secrete albumin and apolipopro-
tein B [7]. Patients with liver damage almost always have 
hypoalbuminemia caused by decreased albumin synthesis 
by the hepatocytes [23]. Data from a large cohort of patients 
revealed that ZZ AAT carriers have markedly reduced serum 
triglyceride and VLDL cholesterol concentrations com-
pared to non-carriers [24]. In the model, we not only con-
firm that differentiated hepatocyte organoids express ALB, 
SERPINA1, CYP3A4 and APOB, but also demonstrate that 
organoids from ZZ AAT individuals have lower expression 
of ALB and APOB in comparison to organoids from MM 
AAT. These findings further confirm that organoids from 
different genetic variants of AAT recapitulate specific fea-
tures of the condition.
As an acute phase reactant protein, expression of AAT 
increases in response to various stimuli. Specifically, in 
the liver AAT is mainly regulated by IL-6-like cytokines 
including OSM. This process is mediated by the interac-
tion between the hepatocyte promoter of SERPINA1 and an 
OSM response element located at the 3′UTR of the AAT 
gene via the interaction of transcription factors like STAT3 
[25]. We found that OSM significantly up-regulates AAT 
expression in MM and MZ organoids under undifferenti-
ated and differentiated stages, whereas in ZZ organoids AAT 
was up-regulated only after differentiation. Currently, we 
are not able to explain these latter differences; however, the 
results provide clear evidence that organoids represent a 
Fig. 4  PAS-D staining for the detection of Z-AAT protein aggre-
gates. Differentiated hepatocytes from MM organoids did not show 
PAS+ staining, while the MZ and ZZ organoids show evident aggre-
gates of Z polymers. Microscope Leica DM 2000, camera Leica 
DFC450 and software LAS v4 (magnification ×40)
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good model to study the expression of liver AAT in relation 
to different AAT genotypes.
It is also important to point out that the expression of 
the ST1C4 alternative short transcript of SERPINA1 gene 
was up-regulated by OSM. Interestingly, some differences 
were observed between Z and M organoids. Namely, higher 
induction of the ST1C4 was found in MM and MZ than in 
ZZ organoids after hepatic cell differentiation. The expres-
sion of ST1C4 was previously found in the liver [5]; how-
ever, the transcriptional regulation and functional role of 
this transcript are not clear. The induction of ST1C4 tran-
script in response to inflammatory signal further confirms 
its functional role and encourages further investigations. 
Hypothetically, this transcript can generate C-terminal pep-
tide of AAT, which has been found to regulate bile acid 
synthesis in primary rat hepatocytes in vivo [26].
Based on clinical and experimental data, we have learned 
that hepatocytes from Z-AAT deficiency carriers can be dam-
aged by gain-of-toxic mechanisms activated because of intra-
cellular accumulation of Z-AAT protein [27]. As expected, 
the cultures of hepatic organoids derived from patients carry-
ing Z-AAT mutation revealed intrahepatic aggregates of mis-
folded Z-AAT protein. The intracellular AAT accumulation 
(positive PAS-D staining) and polymerization (immunostain-
ings with specific anti-Z-AAT polymer antibody) were abun-
dant in organoids derived from ZZ and also detected in MZ 
Fig. 5  Immunofluorescence detection of AAT and AAT polymers. a 
Representative pictures of liver organoids in the expansion medium 
(EM) of MM, MZ and ZZ patients (images magnification ×10). b 
Differentiated liver organoids from MM, MZ and ZZ patients. Spe-
cific detection of total AAT protein with anti-AAT-B9 or with anti-
AAT-D11 against AAT polymers, are shown in green fluorescence. 
Zoomed images of individual positive cells are showed in the right 
corner. c Quantification of AAT polymers (D11) positive cells in 
the different organoids MM, MZ and ZZ. Microscope Zeiss Ax10, 
camera Axio Cam Mrm Carl Zeiss and software AxioVision Rel.4.7 
(images magnification ×40)
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subjects. Differently from MM and MZ organoid cultures, 
ZZ organoids showed almost no detectable secretion of AAT 
protein. These findings indicate that liver organoid cultures 
reflect AAT behavior seen in individuals with normal M- and 
mutant Z-AAT, and thus represent a valuable tool to study 
the molecular mechanisms underlying intracellular accu-
mulation and secretion of AAT protein. Since organoids are 
derived directly from the affected individuals, they may also 
help us to elucidate the complex heterogeneity of liver dis-
ease among AATD carriers. In addition to Z-AAT mutation, 
many other rare alleles associated with AAT deficiency have 
been described [19, 28, 29] for which the potential damag-
ing effects in hepatocytes are unknown. Organoids derived 
from patients carrying other than the Z variant would help to 
investigate the mechanisms of accumulation, secretion and 
degradation of these much less studied AAT variants.
Moreover, the development of organoid cultures has 
been successfully reported for other organs derived from 
the endoderm, such as the intestine, stomach, pancreas 
and lung, as well as for other internal organs derived from 
the mesoderm including the kidney, heart, cartilage, bone, 
reproductive organs and muscle, and also for tissues derived 
from ectoderm, both skin and its associated glands and neu-
ral ectoderm, giving rise to the brain, spinal cord and neural 
crest [8]. Organoids have proved very useful for a wide range 
of applications such as modeling human diseases, organo-
genesis and tissue development, drug screening, gene editing 
for monogenic diseases and regenerative medicine [8, 30].
Organoids represent an innovative approach to validate 
specific genetic alterations in the SERPINA1 gene that are 
associated with liver disease development, and furthermore 
to identify and elucidate other genes associated with liver 
disease progression and to investigate putative treatments.
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Fig. 6  Representative western blot detection of AAT protein expres-
sion and secretion in MM, MZ and ZZ differentiated organoids. Blots 
of extracellular, cytoplasmic and insoluble fractions were incubated 
with anti-AAT-B9. The anti-β actin antibody was used as a control 
marker in the cytoplasm extract. Panels of figures were composed to 
show MM, MZ and ZZ AAT in the same order. Relative quantifica-
tion with respect to MM amount of AAT in the extracellular medium 
and in the insoluble fraction of organoids is shown at the bottom
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